Indeed, NSCLC is now almost a poster child for the benefits of precision medicine, with almost 70% of NSCLCs having a biomarker-based therapy (including but not limited to EGFR and ERBB2 alterations, mismatch repair gene defects, high tumor mutational burden, BRAF V600E, NTRK fusions, ALK fusions, ROS1 fusions, and RET alterations) [3,4,5,6,7,8,9,10]. This evidence concerns the gene ERBB2 and neoplasm.